In this review we discuss the contribution of NO, prostacyclin and endotheliumderived relaxing factor -endothelium-derived hyperpolarizing factor, or EDHF, to vascular function. We also explore the hypotheses (1): that tissues can store NO as nitrosothiols (RSNOs) and (2) that such RSNO stores can be modulated by physiological and pathophysiological processes. Notably in the microcirculation, EDHF appears to play an important role in the regulation of vascular tone. Leading candidates for EDHF include extracellular potassium (K + ), an epoxygenase product, hydrogen peroxide and/or a contribution from myoendothelial gap junctions. Data from our laboratory indicate that in mouse vessels, different endothelium-dependent vasodilators, such as acetylcholine and protease-activated receptor (PAR) agonists, release different endothelium-derived relaxing factors. The combination of two K-channel toxins, apamin and charybdotoxin, inhibits EDHF activity in most protocols. Endothelial dysfunction is considered as the major risk factor and a very early indicator of cardiovascular disease including the cardiovascular complications of type I & types II diabetes. Impaired endotheliumdependent vasodilatation results primarily from a decreased synthesis of endotheliumderived nitric oxide (NO) and/or an increase in the production of reactive oxygen species such as superoxide. We have shown that the administration of tetrahydrobiopterin, an important co-factor for nitric oxide synthase (NOS) partially restores endothelial function (1) in leptin-deficient mice (db/db) with spontaneous type II diabetes, as well as (2) in human vascular tissue harvested for coronary artery bypass grafting (CABG). These data suggest that a deficiency in the availability of tetrahydrobiopterin plays an important role in vascular dysfunction associated with Type II diabetes. In addition, changes in the contribution of EDHF occur in vascular tissue from the db/db mice suggesting a compensatory increase in EDHF production; whether this alteration in EDHF production is physiological or pathophysiological remains controversial.
Invited Review

The Endothelium in Health and
Introduction
The endothelium plays a key role in the short-and long-term regulation of the cardiovascular system and is the source of many factors that influence blood flow, blood coagulation as well as angiogenesis. A key factor produced by the endothelium is the gas, nitric oxide, NO. NO is an important vasodilator that also possesses platelet anti-aggregatory and pro-(and anti-) angiogenic activity. However, the synthesis and release of other vasoactive factors may also be altered in disease states and that may also contribute to endothelial dysfunction has yet to be explored in depth.
A Healthy Endothelium is Anti-Atherogenic
Collectively, the endothelium is a major "organ" in the body. In an adult, the total endothelium mass is about 500 grams, located mainly in the pulmonary circulation. The endothelium is formed by a single layer of cells lining the inner wall of the vasculature, serving both as a semi-permeable barrier and as a regulator of vascular tone by releasing various vasoactive substances: vasodilators (nitric oxide, prostacyclin, endothelium-derived hyperpolarizing factor, bradykinin, adrenomedullin, C-natriuretic peptide), vasoconstrictors (endothelin-1, angiotensin-II, thromboxane A2, prostaglandins, hydrogen peroxide (H2O2) and free radicals) (McGuire et al., 2001) . The L-arginine-nitric oxide (NO) pathway is thought to be the most important enzymatic vasodilator source. In addition to its function as a vasodilator, NO released from endothelial cells is also a potential inhibitor of the aggregation and adhesion of platelets to the vascular wall. NO also controls the expression of proteins involved in atheroma formation, decreasing the expression of the chemo-attractant protein MCP-1, and of surface adhesion molecules such as CD11/CD18, P-selectin, VCAM-1 and ICAM-1 (Li and Forstermann, 2000) . Additionally, NO reduces vascular permeability and decreases the rate of oxidation of low-density lipoprotein (LDL), thereby preventing the pro-atherogenic effect of LDL, and inhibiting the proliferation of vascular smooth muscle cells. Endothelial function can be readily measured in both animal models and in humans. In humans, the status of the endothelium is thought to be an important surrogate marker of atherosclerotic activity (Anderson, 1999; Verma and Anderson, 2002) . A reduction in the bio-availabilty of NO (defined as endothelial dysfunction resulting from a reduced vasodilatory response to acetylcholine) can result in cardiovascular dysfunction, with a concomitant increase in morbidity and mortality. Several recent studies have demonstrated that attenuation of endothelium-dependent vasodilation is associated with an increased risk of cardiovascular complications during long-term follow-up. These data point to the endothelium as an appropriate therapeutic target (Halcox et al., 2002) .
NO Stores in Tissues
As already stated, one of the most important substances that the endothelium produces is nitric oxide, or NO. NO is released from the endothelium either by "chemical activation" such as by the neurotransmitter, acetylcholine (ACh), or by "mechanical activation" as a result of the shear stress created by blood flowing across the endothelium. NO is synthesized within the endothelial cells from L-arginine via the action of endothelial nitric oxide synthase (eNOS) and it is thus assumed that the cellular source of NO in the vasculature is derived from one of the three isoforms of NOS (i.e., eNOS, neuronal NOS, termed nNOS, or the inducible NOS, iNOS). However, an increasing body of data suggests that there is a comparatively stable store of NO in vascular tissues and that the origin of this store cannot be linked causally to the activity of eNOS (Andrews et al., 2002; Andrews et al., 2003) . These data suggest that there is more than one mechanism whereby NO can be synthesized in endothelial cells, that NO can be stored in endothelial and vascular smooth muscle cells, and that this "pre-formed NO" can be released from the cells by physiological stimuli. Most likely NO is stored in tissues as nitrosothiols (RSNOs). We have explored the contribution of such stores to the photorelaxation phenomenon that was first described by Furchgott et al. (1955) and Andrews et al. (2002 Andrews et al. ( , 2003 . Figure 1 summarizes potential mechanisms whereby such stores can be modulated.
Role of Thiols
NO may be stored as labile NO-releasing intermediate compounds containing a thiol-NO linkage and the sulfhydryl moiety to which NO attaches is found in the side chain of cysteine, homocysteine, glutathione or the cysteine sulfhydryls present in proteins such as the abundant albumin. S-nitrosothiol compounds, or RSNOs, (Stamler et al., 1992) may be critical determinants of the activity, transport and metabolic fate of NO. Adduct compounds such as Snitrosocysteine (CysNO), S-nitrosoglutathione (GSNO) and S-nitroso-acetyl penicillamine (SNAP) can either decompose to liberate NO, and, as such, possess potent smooth muscle relaxant activity; or, such compounds may be involved in transnitrosation and S-thiolation reactions where they can affect signal transduction and enzyme activity. RSNOs have also been shown to inhibit platelet aggregation, and have longer half-lives than NO itself (Feelisch et al., 1994) . RSNOs have also been implicated to play a critical role in stress responses such as hypoxia (Lipton et al., 2001) . The reaction between NO and thiols is dependent on the presence of oxygen and the one-electron oxidation product of NO, NO + , which is more likely to react with thiols than NO
• to form nitrosothiols (Stamler et al., 1992) . Some RSNOs are polar or too large to readily cross cellular membranes. Therefore, the entry of NO from RSNOs into cells is thought to involve a process called trans-nitrosation, where NO + is transferred from one thiolcontaining protein to another to ultimately elicit its signal (Liu et al., 1998) . RSNOs may also mediate their cellular effects through stereo-specific receptor activation, particularly in the CNS (Davisson et al., 1997) . Similar functions for NO stores in the vasculature are also likely. We have recently begun to explore this hypothesis and have been able to measure the nitrosothiol, S-nitrosoglutathione (GSNO), in vascular tissue and demonstrate that such stores can be modulated by light:
Using analytical techniques recently developed in our laboratory, we have been able to quantify the nitrosothiol, S-nitrosoglutathione (GSNO), and its major NO decomposition product, nitrite, in vascular tissues. High Performance Liquid Chromatography (HPLC) was employed for the measurement of GSNO in mouse aortic tissues. In brief, tissues were homogenized in ice-cold phosphate buffer (50 mM, pH 7.4) containing N-ethylmaleimide (5 mM) using a glass homogenizer, and the resulting homogenate was immediately analyzed after trichloroacetic acid (TCA: 2%) precipitation of proteins. Extracts were injected into an Agilent 1100 Series HPLC system equipped with a Hypersil BDS C18 column (125 × 4 mm, 5 µm) (Agilent Technologies, US) running at a flow rate of 0.55 mL/min using 99% phosphate buffer (50 mM, pH 4.5) and 1% acetonitrile. This method allows direct detection and quantification of GSNO in vascular tissues. Indeed, our preliminary data show that there was a small GSNO store (6 ± 0.7 nM; n=4) ( Fig. 2 ) in mouse aorta, suggesting that NO can be stored in the form of RSNOs. Moreover, we have examined whether ultraviolet (UV) light could induce the release of NO from the GSNO store. results, which is followed by vasodilation. Alternately, NO may be derived from an additional enzyme (ie xanthine oxidase) or a non-enzymatic pathway within the EC or NO liberated from RSNOs outside the cell (possibly from the circulating blood) by the cell surface protein disulfiole isomerase (csPDI) may provide an additional mechanism for the formation of RSNOs inside VSMCs. The liberated NO reacts with O2 in the membrane to form N2O3, which reacts with intracellular thiols (GSH) at the cell cytosol interface to produce RSNOs. NO can also be liberated from RSNOs by irradiation with UV light which homolytically cleaves the S-N bond of RSNOs to release NO. Alternatively, a Cu + containing intracellular enzyme may catalyse the release of NO from RSNOs.
Aortae were repeatedly (six times) exposed to 5 minutes of UV light every 5 minutes for a total of 30 minutes. Interestingly, the minute amount of GSNO was depleted following illumination with light ( Fig. 2) . To support our contention that NO was liberated from the NO stores, we measured the concentrations of nitrite in aortic tissues before and after UV light exposure. Using the DAN fluorometric technique with excitation and emission wavelengths of 380 nm and 450 nm respectively (Misko et al., 1993) , an increase in nitrite was observed after mouse aorta was irradiated with light (data not shown). Our preliminary results demonstrate that vascular GSNO stores can be modulated by light. These data are summarized in Fig. 2 .
Non-NOS Sources of NO in the Vasculature
If NOS is not the sole source of NO, then what is the origin of this NO store? Recent studies have suggested enzyme-independent chemical reactions and/or non-NOS enzymatic sources may be able to generate NO independently of NOS. Indeed, chemiluminescence studies have shown that reactions between L or D-arginine and H2O2 can produce NO (Nagase et al., 1997) . It has been reported that NO can be produced by the reduction of nitrite in the ischaemic heart and it has also been proposed that the acidic-metabolic vasodilatation seen in rat aorta under hypoxic conditions might arise following the conversion of nitrite into NO (Modin et al., 2001) . The production of NO from acidified nitrite is a commonly used approach to generate NO under experimental conditions (Cocks and Angus, 1990 ). As such, it is interesting that a by-product of cellular metabolism and thus a non-enzymatic source of NO could have a physiological (or indeed pathological) role in regulating vascular tone. A potential non-NO synthase enzymatic source is, not surprisingly, cytochrome P450 (CYP), which in addition to being structurally similar to NOS, has been reported to be able to generate NO in a NADPH and oxygendependent manner (Karasu, 2000) . In addition, xanthine oxidase is thought to catalyze the reduction of nitrite to generate NO in the presence of NADH (Zhang et al., 1998) . The storage (and release) of NO in cells as nitrosothiols provides a provocative argument that NO is not simply an autocrine, or paracrine signal, but that it may also function as a true blood/tissue borne hormone. We hypothesize that NO is released from a store in one cell and, because of its unique ability to cross cell membranes readily, acts on distant cells either to "signal" a cell response and/or to be stored as a nitrosothiol. Thus, the hypothesis originally brought forward by Liu et al., (1998) may have far reaching physiological consequences.
EDHF
EDHF is defined as a mediator of vascular relaxation via a non-NO and non-prostaglandin mechanism, notably in resistance arteries where NO appears to have less prominence than in conduit vessels (McGuire et al., 2001) . There are several candidates that have been identified that may represent physiological 'EDHFs' viz., NO per se, L-citrulline, potassium ions, anandamide, epoxyeicosatrienoic acids (EETs) and H2O2. The EETs are potential candidates for endothelium-derived hyperpolarizing factor (EDHF) because they hyperpolarize and relax vascular smooth muscle cells by activating calcium-sensitive potassium channels. EETs are the product of CYP activity (see review by McGuire et al., 2001) . In situations of reduced endothelial NO availability (for example, in eNOS knock out mice), there is an up-regulation of EDHF-mediated relaxation in resistance arteries (Waldron et al., 1999; Ding et al., 2000) . Reduced bioavailability of NO will remove the inhibitory action of NO on haem-containing enzymes such as cytochrome P450 (CYP) (and also nitric oxide synthase, NOS). In ongoing work, we have demonstrated that these products may be up-regulated in the db/db mouse (Pannirselvam et al., 2003) (Fig. 3) .
Regulation of EDHF by K-channels
Calcium-activated K-channels play an important role in the regulation of vascular tone and the actions of EDHF. Ca 2+ -activated K + channels (KCa) can be sorted into three classes A to C: Bradykinin-induced EDHF-(non-NO, non prostaglandin) mediated relaxation is sensitive to a combination of blockers of IKCa (charybdotoxin) and SKCa (apamin) as well as to a combination of inhibitor/blocker of Na/K ATPase (ouabain) and KIR channel (barium), but not to blocker of BKCa (iberiotoxin) whereas bradykinin-induced EDHF-mediated relaxation is sensitive to blocker of BKCa (iberiotoxin) and probably mediate through 17-ODYA sensitive pathway namely EETs.
(A) large-conductance (BKCa) channels, sensitive to iberiotoxin. These channels play an important role in vascular smooth muscle cells (VSMC) as a negative feedback, opposing the depolarization initiated by vasoconstrictor stimuli. BKCa channels are also inhibited by low concentrations (1 mM) of tetraethylammonium (TEA) and are the primary target for NOmediated hyperpolarization via, in most instances, the activation of soluble guanylyl cyclase (sGC) although direct activation of BKCa channels by NO has been reported (Bolotina et al., 1994) . One of the candidate EDHF molecular families is the EET family and a number of EETs (5, 8, 11, and 14, have been reported to activate the BKCa, and are iberiotoxinsensitive (Hu and Kim, 1993) . However, BKCa channels have not been shown to be expressed in native endothelial cells (Triggle, 2001) . (B) intermediate-conductance KCa (IKCa) channels, which are inhibited by the toxin charybdotoxin (which also blocks BKCa and certain KV channels); however, IKCa, although present on endothelial cells, are not thought to be of importance in VSMC, at least under normal physiological conditions, and (C) small-conductance KCa (SKCa) channels, which are sensitive to the toxin apamin. Although apamin alone may inhibit responses to EDHF in some vessels, SKCa channels are not universally found in VSMC (Murphy and Brayden, 1995) such that their role in inducing hyperpolarization may be related to their endothelial cell location (Edwards et al., 1998) .
There are three subtypes of SKCa channels, namely the SK1, SK2 and SK3, which are voltageindependent but are activated by a calmodulin-dependent mechanism regulated by intracellular Ca 2+ levels in the submicromolar ranges of Ca
2+
. Their amino acid sequences are unique with no significant sequence similarity, except in the pore region, to other K + -channels. However, there is structural conservation with other K + -channels, such as KV, in that the subunits contain six transmembrane domains (Jan and Jan, 1990 ), but are not voltage-dependent. Our lab has shown that the inhibitors apamin and tubocurarine in combination with the IKCa blocker ChTx block the Ach-induced EDHF-mediated relaxation. Tubocurarine also inhibits the relaxation in the absence of ChTx to the same extent as with the second blocker (Ding et al., 2003) . Apamin and tubocurarine have differing affinities for the SKCa isoforms. Apamin potently inhibits SK2 and SK3 channels more than SK1. On the other hand, curare potently blocked SK2 over SK1 channels (Kohler et al., 1996) . Immunocytochemistry data from our lab has shown an endothelial and smooth muscle cell plasma membrane location for SK3, while SK2 has been found in the nuclear region of smooth muscle and the plasma membrane of endothelial cells (Ding et al., 2003) . Based on these preliminary results and the effects of inhibitors, SK2 may be the likely isoform on the endothelial cells that contribute to the EDHF response.
In many vessels a combination of apamin and charybdotoxin inhibits EDHF activity. Of significance, iberiotoxin usually cannot substitute for charybdotoxin. Since SKCa and IKCa are not thought to reside universally on VSMC it has been suggested that SKCa and IKCa play a critical role in the regulation of either the synthesis and/or release of EDHF and that the channels are most likely located on the endothelial cells (Edwards et al., 1998) . Although the specific location of the SKCa and IKCa channels is not known it may be hypothesized that they should be located primarily ab-luminally and thus facilitate the release of EDHF towards the VSMC. We have begun to explore this hypothesis, and by using immunohistochemical techniques and RT-PCR studies, have examined the distribution of SKCa, IKCa, BKCa channels and preliminary data from freshly dispersed ECs and VSMCs indicates a uniform distribution of SKCa2 and SKCa3 and these data are summarized in Table 1 .
If iberiotoxin is not a universal blocker of EDH then which K-channel(s) on VSMC mediates EDH? What is the VSMC target for EDHF? These are unanswered questions. Furthermore, is there a novel channel KCa in endothelial cells that requires the presence of both apamin and charybdotoxin for inhibition? KCa-channels with unusual characteristics have been described in cell cultures and, for instance, in bovine aortic endothelial cell cultures. Cai et al. (1998) have described an IKCa that has some of the pharmacological properties expected of BKCa and KV1.2 channels. Zygmunt and colleagues (1997) have also argued that a novel SKCa channel may exist that is only sensitive to apamin in the presence of charybdotoxin. Figure 4 depicts the distribution of the potassium channels that regulate the production, synthesis, release and action of NO, PGI2 and EDHF.
Proteinase-Activated Receptors (PAR) and Endothelial Function
Proteinase-Activated Receptors (PARs) constitute a recently discovered family member of the G protein coupled receptor superfamily. As their name implies their activation is mediated by serine proteases in their local environment (Hollenberg and Compton, 2002) . These serine proteinases selectively cleave at specific sites for each PAR to unmask an extracellular Nterminal domain that then functions as a 'tethered ligand' to activate the receptor. These family members were named in chronological order of the discovery of their protein sequences (PAR1, PAR2, PAR3, PAR4). Importantly, PAR1, PAR3 and PAR4 are targeted by the essential bloodclotting enzyme, thrombin, whereas PAR2 is activated by trypsin and tryptase, but not by thrombin. In part because of this distinction in enzyme selectivity between PAR2 and the other PARs, and despite some uncertainty in the nature of endogenous agonist(s), it is proposed that activation of PAR2 may have an important role in the regulation of cardiovascular health.
Amongst the earliest reports regarding the activation of PAR2 in vitro either by enzyme or peptide agonists, was the observation of an endothelium-dependent vasodilation of isolated blood vessels (Hollenberg et al., 1996) . The complete inhibition of vasodilation by an inhibitor of nitric oxide (NO) synthases, L-NAME, clearly indicates that, in most blood vessels, NO mediated the response to PAR2 activation in many blood vessels (Glusa et al., 1997; Moffatt and Sobey and Cocks, 1998) . However, it was observed subsequently that NO produced by the endothelium could not account wholly for vasodilation or the blood pressure lowering effects that resulted from PAR2 activation; nor did products of cyclo-oxygenases (Magazine et al., 1996; Damiano et al., 1999) . Thus, it was proposed that unidentified endothelium-dependent hyperpolarization factor(s) (EDHFs) were involved as well as NO in the vascular responses to PAR2 activation (Emilsson et al., 1997; Hamilton and Cocks, 2000; McGuire et al., 2002; McLean et al., 2002; Trottier et al., 2002) . It should also be noted that the direct activation of PAR2 expressed on the smooth muscle cells results in vasoconstriction of some blood vessels (Moffatt and Cocks, 1998; McGuire et al., 2002) . Therefore, the expression of PAR2 on both ECs and VSMCs influences vascular reactivity. Paradoxically, in experimental models of both chronic hypertension (Spontaneously Hypertensive rats 46) and hypotension (sepsis, 47) the expression of PAR2 has been observed to be up-regulated in vivo. Interestingly, PAR2 expression was also observed to increase during arterial restenosis following balloon angioplasty in yet another animal model (Damiano et al., 1999) . Furthermore, PAR2-mediated vasodilation of coronary arteries was preserved relatively better than that by other endothelial G protein coupled receptors in a model of global cardiac ischemia-reperfusion injury (McGuire et al., 2002) . These data indicate that PAR2 expression increases following stress to the vasculature and this conclusion is consistent with cell culture experiments wherein various cytokines and pro-inflammatory substances induced changes to the cellular expression of PAR2 in ECs and VSMCs (Nystedt et al., 1996; Bono et al., 1997; Molino et al., 1997) . We conclude that PAR2 modulates, either directly or indirectly, vascular tone and blood flow; but for what purpose? And to what end? Figure 5 illustrates the role that PARs play in the regulation of vascular tone.
Endothelial Dysfunction in Diabetes
A reduced vasodilatory response to acetylcholine has been frequently reported in vascular tissue from both humans and animals with diabetes (De Vriese et al., 2000; Pannirselvam et al., 2003) and this observation defines "endothelial dysfunction". Endothelial dysfunction in human penile corpura cavernosa was first reported for type I and type II diabetic patients (Saenz et al., 1989) . Impaired endothelium-dependent relaxation has been reported in the peripheral circulation in type I (Johnstone et al., 1993) and type II diabetic patients (Ting et al., 1996) , evaluated either in vivo or in isolated arteries from these individuals studied in vitro. Exceptions, however, have also been reported (Calles-Escandon and Cipolla, 2001). While hyperglycemia characterizes diabetes and is felt to play an important role in vascular disease, endothelial dysfunction is common in non-diabetics with conditions unrelated to diabetes, including hypertension and dyslipoproteinemias. In addition, it has been shown that endothelial dysfunction occurs in insulin-resistant obese individuals prior to the development of diabetes (Steinberg et al., 1996) .
Clinical studies support the hypothesis that both acute and chronic hyperglycemia plays an important role in the endothelial dysfunction that eventually leads to diabetic vascular complications (Williams et al., 1997; Makimattila et al., 1999) . Several studies observed improvement of endothelial function with anti-hyperglycemic agents supporting the hypothesis that hyperglycemia is the major risk factor in endothelial dysfunction in diabetes (Mather et al., 2001) . In human studies it is often difficult to separate hyperglycemic effects from those due to other metabolic modulating effects of pharmacological agents. Therefore to test this hypothesis further, we have compared endothelial function in three different mouse models of insulin resistance/type II diabetes viz., db/db (mutation in the gene encoding one of the isoforms of the leptin receptor), ob/ob (mutation in gene encoding for leptin secretion) and TallyHo mice (polygenic defect). Only db/db and Tallyho mice exhibit hyperglycemia & dyslipidemia whereas ob/ob mice have dyslipidemia, but are normoglycemia. Further, db/db and TallyHo mice, but not ob/ob mice show an impaired relaxation to acetylcholine. These data confirms that hyperglycemia is the major risk factor in the endothelial dysfunction and vascular complications. We believe that hyperglycemia increases oxidative stress from different sources, which in turn decreases the bio-availability of tetrahydrobiopterin, an important co-factor for nitric oxide synthase, leading to "uncoupled" eNOS. "Uncoupled" eNOS generates superoxide instead of nitric oxide resulting in endothelial dysfunction (Fig. 6) . EETs may also serve as ligands for PPARs (peroxisomal proliferator activated nuclear receptors) (Cowart et al., 2002) . This link with the PPARs is of importance since the expression of some CYP isoforms is under the control of PPARα. PPARγ agonists (such as rosiglitazone and pioglitazone) target insulin resistance and play a therapeutic role not only in the treatment of insulin resistance but also in modulating the inflammatory response associated with diabetes (Murphy and Holder, 2000) . Glitazones have also been shown to improve endothelial function in the OLETF rat model of type II diabetes and obesity (Yamagishi et al., 2001) . The synthesis of EETs may also be up-regulated in the db/db mouse.
Changes in Endothelial Function in Disease States and the Contribution of Reactive Oxygen Species (ROS)
Endothelial dysfunction appears to be a common, and early, feature of cardiovascular disease. The exact etiology of the cellular basis for this dysfunction is not clear, however, as discussed in conjunction with our data from mouse models of type II diabetes, an elevation of intracellular oxidative stress may well be the common denominator. Nonetheless, the trigger for this dysfunction may be disease specific. Although eNOS-derived NO is a key factor for maintaining a healthy endothelium, changes in the contribution and/or nature of other endothelium-derived vasodilators may also be an important consideration. In this regard, the contributions of H2O2 and C-Reactive Protein (CRP) merit consideration.
Reactive oxygen species (ROS) such as hydrogen peroxide appear to serve as physiological signalling molecules in the vasculature. Hydrogen peroxide (H2O2) is both a direct vasodilator itself (Wei et al., 1996; Iida and Katusic, 2000) and also elicits endothelium-dependent vasodilatation in some arterial beds. Endothelium-dependent relaxations mediated by H2O2 have been reported in cat (Kontos et al., 1984) , rat (Yang et al., 1991; Sobey et al., 1997) and mouse cerebral arteries (Rosenblum, 1987) , in canine coronary arteries (Rubanyi and Vanhoutte, 1986) , in mouse mesenteric arteries (Matoba et al., 2000) and in human vasculature (Matoba et al., 2002; Miura et al., 2003) . Some of the mechanisms for the generation of H2O2 and the sites of action of H2O2 on vascular smooth muscle are depicted in Fig. 7 .
Although these studies did not identify the enzymatic source of H2O2, ECs have been shown to generate significant amounts of ROS (Stroes et al., 1998; Vasquez-Vivar et al., 1998) and ECs express enzymes (e.g. eNOS, NADPH oxidase, CYP, COX) that can produce ROS in response to receptor activation or other cellular events that elevate intracellular calcium. NO is the principal endothelium-derived dilator operating in the vasculature and its activity can be governed by the amount of ROS in the vascular milieu, whereby superoxide anions can rapidly scavenge NO at a diffusion-controlled rate (Beckman et al., 1990) . NO displays high affinity for haem groups and many enzymes, including those noted above (NOS, COX, CYP etc) have haem groups, thus NO itself may inhibit the enzymatic production of superoxide and H2O2 (Griscavage et al., 1994; Stadler et al., 1994) . The relative contributions of NO and ROS to vascular tone are inversely proportional to each other and the appearance of one could likely compensate for the absence of the other. Pathophysiological conditions such as diabetes and atherosclerosis display signs of oxidative stress and dysfunctions in the NO pathway, thus it may be valid to argue that endothelial ROS production could be compensating for impairments to normal relaxant mechanisms. If this hypothesis is correct then there should be an increased contribution of H2O2 in pathophysiological states where the normal production of NO is compromised. However, other than a study by Cosentino et al. (2001) , which reported an increased contribution by H2O2 to endothelium-dependent relaxations in tetrahydrobiopterin-deficient mice, there is little evidence to support this hypothesis. For example, Yang and others (1991) showed that endothelium-dependent relaxations to bradykinin in pial arteries from either normotensive or hypertensive rats were both similarly sensitive to catalase. In addition Matoba and colleagues (2000) identified H2O2 as an endothelium-dependent vasodilator in mesenteric arteries obtained from both eNOS-expressing and eNOS-deficient mice. It should also be noted that studies by other groups (Itoh et al., 2003; have disputed the conclusions of Matoba et al. (2000) . Nevertheless, additional studies should be performed in order to determine whether increased reliance on ROS as physiologically-relevant endothelium-derived relaxants occurs in selective vascular beds or in specific arterial diseases, and to correlate this to the level of oxidative stress under such conditions.
C-Reactive Protein (CRP) Effects on Endothelial and Vascular Smooth Muscle Cell Function
Arterial inflammation is now recognized as an indicator of the development and progression of atherothrombosis and C-reactive protein (CRP) has proved to be a well studied risk factor and indicator of the level of atherosclerosis (Bhatt and Topol, 2002; Libby et al., 2002; Taubes, 2002) . In addition to these actions CRP has also been shown to decrease NO production in human saphenous vein and umbilical vein endothelial cells via an effect on eNOS mRNA stability (Verma et al., 2002) and thus, via decreased NO production, inhibited angiogenesis. ) reduced by superoxide dismutase (Cu/Zn SOD) form cell-permeable hydrogen peroxide (H2O2), which can diffuse across cellular membrane to act on cellular targets or it may undergo further metabolism (by catalase or transition metal cations). Putative cellular targets of H2O2 that could result in dilatation include potassium channel sulfhydryl groups (KATP, KCa, KV) -resulting in increased or decreased channel permeability; guanylate cyclase-elevated cGMP levels; phospholipase A2-increased arachidonic acid production available to activate KCa channels.
Comparable data have also been reported for human aortic endothelial cells (Venugopal et al., 2002) . Furthermore, CRP has been shown to have an endothelium-independent vasorelaxation action, possibly via a direct action on potassium channels, in human internal mammary arteries obtained from patients undergoing coronary artery bypass surgery (Sternik et al., 2002) . Recent data from our laboratory indicate that CRP has both direct effects and indirect effects on vascular tone in blood vessels from the mouse. We have shown that CRP has endotheliumindependent actions that lead to relaxation of vascular smooth muscle and this would appear to result from the opening of vascular K-channels ( Fig. 8a and 8b) . In addition the incubation of mouse aorta with CRP results in the reduction of acetylcholine (ACh), but not isoproterenol or NO,-mediated relaxation (Fig. 8c) . These latter effects of CRP are clearly endotheliumdependent and are likely due to the effects of CRP on eNOS mRNA stability as already described for CRP on human endothelial cells by Verma et al. (2002) . 
